Why the study?
Does LMWH reduce venous thromboembolic risk compared to UFH in hospitalized medical patients?
Does LMWH reduce venous thromboembolic risk compared to UFH in hospitalized medical patients?
LMWH is superior to UFH for DVT prevention in hospitalized medical patients, though neither treatment impacts overall mortality.
May favor LMWH over UFH for DVT prophylaxis in medical inpatients; leaves open mortality effects and needs RCT confirmation.
Both UFH and LMWH reduce venous thromboembolic risk in hospitalized medical patients, but neither agent alters mortality. When directly compared, LMWH is more effective in preventing DVT.
No takes yet. Share an insight, caveat, or question.
Lironne Wein (2007) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: